AbbVie execs say biosimilar competition to Humira is eroding profits, ‘but we have a plan’

AbbVie executives sought to reassure investors during a Wednesday call that its pipeline will more than plug up any holes that biosimilars might leave.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.